{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Plasma levels of pro-inflammatory cytokines using flow cytometry.","groups":[{"description":"IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks per dosing schema to determine the maximum tolerated dose (MTD)\n\nIL-15 plus: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.\n\nalemtuzumab: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.","id":"OG000","title":"Level 1 - 0.5 mcg/kg/Dose of Interleukin 15 (IL-15) Followed by Alemtuzumab"},{"description":"IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks\n\nIL-15 plus: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.\n\nalemtuzumab: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.","id":"OG001","title":"Level 2 - 1 mcg/kg/Dose of Interleukin-15 (IL-15) Followed by Alemtuzumab"},{"description":"IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks\n\nIL-15 plus: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.\n\nalemtuzumab: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.","id":"OG002","title":"Level 3 - 2 mcg/kg/Dose of Interleukin 15 (IL-15) Followed by Alemtuzumab"}],"populationDescription":"These analyses were not performed because there was pan lymphocyte depletion with the initiation of Campath (alemtuzumab) treatment and flow cytometry was not performed and there were not enough circulating lymphocytes to analyze.","reportingStatus":"POSTED","timeFrame":"At 6 weeks of treatment","title":"Plasma Levels of Pro-inflammatory Cytokines","type":"SECONDARY"}